HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ('Hims & Hers' or 'the Company') (NYSE: HIMS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Hims & Hers is the subject of an announcement by Novo Nordisk issued on June 23, 2025. According to Novo Nordisk, it is ending its relationship with the Company 'due to concerns about their illegal mass compounding and deceptive marketing.' According to the press release, 'the FDA resolved the Wegovy ® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy ® through NovoCare ® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Based on this news, shares of Hims & Hers fell by more than 32.4% in afternoon trading on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Can Verizon's Cash Flow Cover Its Dividend Long-Term?
Verizon Communications Inc. (NYSE:VZ) is one of the Best Dividend Leaders to Buy Now. The company has increased its dividend every year for the past 18 years. As the largest wireless carrier in the US, it operates a stable business that generates a large amount of free cash flow, which helps ensure a secure and growing dividend. A smiling customer receiving customer contact center solutions on their smartphone. In the first quarter of 2025, Verizon Communications Inc. (NYSE:VZ) reported a strong cash position. Operating cash flow reached $7.8 billion, up from $7.1 billion in the same period of 2024. Free cash flow was $3.6 billion, compared to $2.7 billion in the first quarter of 2024. For the full year 2025, Verizon Communications Inc. (NYSE:VZ) expects operating cash flow to be between $35.0 billion and $37.0 billion, with free cash flow projected between $17.5 billion and $18.5 billion. In addition, the company's balance sheet remains healthy, with a leverage ratio of 2.3 for its unsecured debt (calculated as net unsecured debt divided by trailing 12-month adjusted EBITDA). Considering this strong financial position, Verizon Communications Inc. (NYSE:VZ)'s dividend appears secure and well-positioned for future growth. The company offers a quarterly dividend of $0.6775 per share and has a dividend yield of 6.4%, as of June 23. Verizon Communications Inc. (NYSE:VZ) is an American telecommunications company that provides a range of wireless and wireline communication services and products, including corporate networking solutions, data center and cloud services, and security and managed network services. While we acknowledge the potential of VZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Goldman Sachs Initiates Coverage on Hormel with a Buy Rating
Hormel Foods Corporation (NYSE:HRL) is one of the Best Dividend Leaders to Buy Now. On June 23, Goldman Sachs started coverage of Hormel with a Buy rating and set a price target of $35. The firm highlighted the company's 'strong protein demand' as a key reason for its positive view. A close-up of a hand cutting fresh turkeys, revealing the perishable products of the company. Goldman also pointed to Hormel's robust packaged food lineup, featuring a variety of brands, price ranges, and options across important protein categories, as the main drivers of its optimistic stance. The firm made the following comment: 'We expect near-term supply reductions in turkey to support our Buy rating on HRL, along with its solid packaged food portfolio, including a recovery in its Planters nut business.' Hormel Foods Corporation (NYSE:HRL) is a solid dividend company, having raised its dividends for 59 consecutive years. The company currently offers a quarterly dividend of $0.29 per share and has a dividend yield of 3.76%, as of June 23. While we acknowledge the potential of HRL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
an hour ago
- CBS News
San Francisco pharmacy established in 1908 will close its doors in July
It's the end of an era for one longtime pharmacy drugstore in San Francisco. Central Drug Store in the Excelsior District will be closing its doors on July 15 after over 100 years. Owner Jerry Tonelli announced he will be retiring. "This is my father here, Dino Tonelli. He started working here in 1949 after he graduated from pharmacy school at UCSF. And he was a WW2 veteran," Jerry Tonelli, the pharmacist owner of Central Drug Store, told CBS News Bay Area. Generations of San Franciscans have picked up their prescriptions since the pharmacy first opened in 1908, and it's been at the 4494 Mission Street location since 1918, according to its Legacy Business Registry application. "You come in, you know these people, you know their children," Tonelli said. "Sometimes you feel like you're a priest or psychiatrist because they come in with problems, and you try to help them out." The business is also the scene of a sweet love story: His parents met at the drug store, as his mother was also an employee. "My mother started working here when she was 16, and she died in 2023 at the age of 96. So, she had quite a run here, and this was her favorite part of the store because she used to do all the buying for the cosmetics, for the perfumes," Tonelli said. His parents eventually took ownership of the pharmacy and have been prominent community members. "I was only in my 30s when my father passed away, and all of a sudden, to take over the business and run it, was learning by trial and error," Tonelli said. He adds that it has been a great run, meeting new friends along the way. "We get a lot of people from other countries that don't have health insurance and don't want to see a doctor. They'll come in and ask this and ask that and try to treat them with over-the-counter medication to help them out," he said. And now, he shared that his decision to close is bittersweet. Tonelli said he is concerned about independent pharmacies that are essentially being forced out by corporations. "The city started letting Walgreens come into the city, and what happened then was they usually opened up next to the independent, and eventually the independent had to close," he said. Fran Colombo, who has been going to Central Drug Store for the past 50 years, has been hit hard by the news of the closure. She said the Tonelli family has become great friends throughout the years. "They make everybody feel that walks through that door, that they're special," Colombo said. "There are just no words to explain the love that they give out. And in turn, you give it back to them." She shared how Tonelli had helped her late husband when he was picking up his medications. "When he came out, Jerry had his arm and was walking him to our car. And I will never forget that. That is what you call going above and beyond," Colombo said. She added that it is concerning for older patients in the community who don't have many resources to access the healthcare they need. "I'm kind of computer savvy, but what about the people who aren't, who are just used to the walking in and calling in a prescription and walking in and picking it up? What are they going to do?" Colombo said. She said that she will cherish all the memories that she and her family made along the way at their pharmacy. And in the meantime, Tonelli plans to continue providing the best care while he is still open. He added, he is also looking forward to spending time with his family and sharpen his golf skillsets. Tonelli wanted to share that his passion to serve won't stop. "Try to do some volunteer work somewhere and try to help the people out at a hospital or a shelter," he said. Until he writes his last prescription, Tonelli will be right here opening his doors with a smile, like he's been doing all this time.
